Loxo & Illumina team up for diagnostic tool targeting cancer

Apr 10, 2018

Loxo Oncology and Illumina are partnering up on a diagnostic tool, seeking approval for a version of Illumina’s test, TruSight Tumor 170, which will let local labs provide referring physicians with genomic information and have patients be better matched to appropriate therapeutic options.

Larotrectinib directly targets an acquired genetic defect called TRK fusions, which triggers accelerated cancer cell growth in patients. Up to 5,000 U.S. patients a year are diagnosed with the TRK defect.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments